← Leaderboards
Sara Barmettler
Massachusetts General Hospital
$1,093,926
Attributed
$1,093,926
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $261.9K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,093,926 · 1
By mechanism
K23$1,093,926 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Andrew D Luster$52,151,359
- David Kc Cooper$22,744,194
- Sarita U Patil$5,702,646
- Edward T. Ryan$44,052,519
- Kimberly Gold Blumenthal$4,876,153
Others in their field
Other Emerging Leaders on “Immune”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,310,675
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Tony Moody · Duke University$66,767,417
Research focus
ImmuneInfection RiskEnvironmentHypogammaglobulinemiaImmunologicsInfectionCost EffectiveEarly InterventionEpidemiologyHematologic NeoplasmsImmunologic MonitoringB Cell TherapyBiometryImmunologyB-LymphocytesClinical EpidemiologyClinically SignificantClinical ResearchClinical RiskCohortCommunicable DiseasesGeneral HospitalsCar T Cell TherapyInstructor
Grant awards (8)
Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy$191,878
K23 · FY2025 · AI · contact PI
Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy$191,878
K23 · FY2024 · AI · contact PI
Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy$41,731
K23 · FY2024 · AI · contact PI
Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy$28,269
K23 · FY2024 · AI · contact PI
Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy$193,860
K23 · FY2023 · AI · contact PI
Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy$196,560
K23 · FY2022 · AI · contact PI
Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy$54,000
K23 · FY2022 · AI · contact PI
Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy$195,750
K23 · FY2021 · AI · contact PI